Latest BioArctic News & Updates

See the latest news and media coverage for BioArctic. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioArctic

Research-oriented biopharma company for neurodegenerative diseases

bioarctic.com

Headquarters: Stockholm, Sweden
Founded year: 2003
Company type: Public company
Number of employees: 150–200
Industry: Pharmaceuticals

Last updated October 29

Latest news about BioArctic

In short: BioArctic posted 74% Q3 royalty growth and expanded Leqembi access and partnerships.

Company announcements

October 29 BioArctic

BioArctic secures Novartis partnership and reports record royalties

The company signed a new BrainTransporter deal with Novartis for USD 30 million upfront. Leqembi royalties hit SEK 162.5 million in Q2 2025, driven by strong global sales growth.

October 28 BioArctic

BioArctic royalty increases 74 percent in third quarter 2026

Leqembi sales reached 32.2 billion yen, driving royalties of SEK 203.8 million for BioArctic compared to the previous year.

August 24 BioArctic

BioArctic announces Leqembi Iqlik US initiation treatment launch

The subcutaneous autoinjector enables convenient at-home administration, reducing clinic visits and healthcare resource utilization for early Alzheimer’s patients.

August 19 BioArctic

BioArctic reports Q2 results and announces new partnerships

Highlights include SEK 247.5 million in net revenue, FDA approval for a subcutaneous Alzheimer’s drug formulation, and strategic collaborations with Eli Lilly and Mesenkia Therapeutics.

Media coverage

September 22 MarketScreener

Bioarctic AB Announces Leqembi Is Available At A Private Clinic in Sweden

BioArctic AB (publ) announced that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is...

September 15 Finanznachrichten

BioArctic: Leqembi Pen subcutaneous formulation approved in Japan

BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi...

August 31 BioSpace

Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - BioSpace

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study...

August 26 Yahoo Finance

Eli Lilly (LLY) Adds Alzheimer’s Research Deal As Obesity Cost Data Builds

Eli Lilly (NYSE:LLY) agreed a new research and collaboration deal with BioArctic that applies BioArctic's BrainTransporter ...

Never miss news about BioArctic

Track BioArctic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioArctic competitors & trending companies

Browse news for competitors to BioArctic and other trending companies.